$698.27
Value $790B
MU and NUTX stock compared: price, dividend, valuation and results, from SEC filings.
$698.27
Value $790B
$171.95
Value $1.2B
Micron Technology (MU) has a market value of $790B and Nutex Health (NUTX) $1.2B. Over the last year, with dividends, MU moved +183.2% and NUTX +60.5%. The P/E is 9.3 for MU and 7.3 for NUTX. Dividend yield: MU 0.08%, NUTX none.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MU$790B
NUTX$1.2B
MU is 659 times NUTX
Revenue, 12 months
MU$133B
NUTX$797M
MU is 167 times NUTX
Net income, 12 months
MU$85.0B
NUTX$165M
MU is 516 times NUTX
Operating margin
MU74.6%
NUTX39.0%
35.6 points apart
ROIC
MU89.7%
NUTX61.1%
28.6 points apart
P/E
MU9.3
NUTX7.3
MU is 1.3 times NUTX
Dividend yield
MU0.1%
NUTX0.0%
0.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MU+809.1%
NUTX+394.8%
| Period | MUWith dividends | NUTXWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +183.2%Price +182.9% | +60.5%Price +60.5% |
| 3 years since November 17, 2023 | +809.0%+108.7% a yearPrice +800.2% | +396.2%+70.6% a yearPrice +396.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MUMicron TechnologyNUTXNutex Health
| Price | $698.27 | $171.95 |
|---|---|---|
| Market value | $790B | $1.2B |
| Enterprise value (EV) | $752B | $1.3B |
| P/E | 9.3 | 7.3 |
| P/E, 5-year median | 12.9 | – |
| P/B | 5.7 | 2.8 |
| EV/EBIT | 7.6 | 4.1 |
| Free cash flow yield | 7.5% | 20.7% |
| Revenue, 12 months | $133B | $797M |
|---|---|---|
| Net income, 12 months | $85.0B | $165M |
| Free cash flow, 12 months | $59.0B | $248M |
| Earnings per share, 12 months | $74.33 | $23.22 |
| Revenue growth, year on year | 256.3% | 82.4% |
| Revenue growth a year, past | +36.9%over 5 years | +26.1%over 5 years |
| EPS growth a year, past | +70.6%over 5 years | -17.2%over 5 years |
| Gross margin | 80.7% | 47.8% |
|---|---|---|
| Operating margin | 74.6% | 39.0% |
| Net margin | 63.8% | 20.7% |
| ROIC | 89.7% | 61.1% |
| ROE | 100.1% | 45.2% |
| Cash | $43.4B | $250M |
|---|---|---|
| Total debt | $5.2B | $365M |
| Net debt / EBITDA | -0.4 | 0.3 |
| Interest cover | 937.2× | 16.2× |
| Dividend yield | 0.1% | – |
|---|---|---|
| Dividend per share, 12 months | $0.57 | – |
| Dividend growth a year, past | – | – |
| Buyback yield | 0.1% | 0.4% |
| Shareholder yield | 0.2% | 0.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Micron Technology ($790B) is about 659.4 times Nutex Health ($1.2B), at today's prices.
Since November 17, 2023, MU's price moved +800.2% and NUTX's +396.2%. With dividends: MU +809.0% (+108.7% a year), NUTX +396.2% (+70.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.08% for Micron Technology and none for Nutex Health. Over the last twelve months they paid $0.57 and – per share.
At today's price, the P/E is 9.3 for MU and 7.3 for NUTX. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 63.8% for Micron Technology and 20.7% for Nutex Health, and the operating margin 74.6% and 39.0%. Revenue was $133B and $797M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.